Aaron Gerds, MD from Cleveland Clinics discusses phase I-II trial of Glasdegib in myelofibrosis and that Glasdegib is a Hedgehog Pathway Inhibitor at the 2017 American Society of Hematology.
Phase I-II Trial of Glasdegib in Myelofibrosis – Glasdegib is a Hedgehog Pathway Inhibitor
